Full Text View
Tabular View
No Study Results Posted
Related Studies
Otoprotection With SPI-1005
This study is enrolling participants by invitation only.
Study NCT01444846   Information provided by Sound Pharmaceuticals, Incorporated

First Received on September 29, 2011.   Last Updated on November 30, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Temporary Auditory Threshold Shift
Interventions listed in this trial
SPI-1005 Low dose
SPI-1005 Middle dose
SPI-1005 High dose
Placebo
Additional drug interventions recognized in this trial
Ebselen
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Anti-Ulcer Agents
Antioxidants
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Sound Pharmaceuticals, Incorporated
University of Florida


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services